文献速递母胎医学产科

全基因组测序在产前及婴儿期先天畸形中相较于染色体微阵列分析和外显子组测序的增量检出率:系统评价与Meta分析

Incremental yield of whole-genome sequencing over chromosomal microarray analysis and exome sequencing for congenital anomalies in prenatal period and infancy: systematic review and meta-analysis.
PubMed 文献 · Ultrasound Obstet Gynecol · 2024-01-01

该系统评价纳入18项研究共902例具有产前超声可检测的先天畸形且QF-PCR和CMA阴性的胎儿、新生儿或婴儿,旨在评估全基因组测序(WGS)相较于QF-PCR/CMA及外显子组测序(ES)的增量检出率。结果显示WGS相较于QF-PCR/CMA的合并增量检出率为26%(95%CI 18-36%),产前队列为16%(95%CI 9-24%),产后队列为39%(95%CI 27-51%);WGS相较于QF-PCR/CMA和ES的增量检出率仅为1%(95%CI 0-4%)。WGS所需DNA量较少且周转时间可能更短,但意义不明变异(VUS)检出率较高。

要点

  • WGS相较于QF-PCR/CMA的增量检出率在产后队列为39%,高于产前队列的16%。
  • WGS相较于QF-PCR/CMA和ES的增量检出率仅为1%(95%CI 0-4%),尚未显示出超越ES的增量价值。
  • WGS所需DNA量为100±0 ng,低于QF-PCR/CMA和ES的350±50 ng(P=0.03)。

核心结论

  • WGS在先天畸形病例中前景广阔,但其相较于ES的增量检出率尚未得到证实;WGS所需DNA较少且周转时间可能更快,但VUS检出率相对较高。

研究设计与样本

  • 系统评价与Meta分析,纳入18项队列研究共902例合格病例,其中8项研究(44.4%)为产前队列共755例,其余为产后队列。
  • 检索数据库包括Ovid MEDLINE、EMBASE、MEDLINE(Web of Science)、Cochrane图书馆和ClinicalTrials.gov,检索时间为2010年1月至2022年12月。
  • 纳入标准为队列研究包含3例及以上胎儿、新生儿或婴儿,具有一种或多种先天畸形,畸形在产前超声可检测或本可检测,且QF-PCR和CMA阴性。
  • 采用随机效应模型计算合并增量检出率,使用Higgins I²检验评估异质性。

主要发现

  • WGS相较于QF-PCR/CMA的增量检出率在全部病例为26%(95%CI 18-36%,I²=86%),产前队列为16%(95%CI 9-24%,I²=85%),产后队列为39%(95%CI 27-51%,I²=53%)。
  • 符合NHS England产前ES纳入标准的病例增量检出率为32%(95%CI 22-42%,I²=70%),多系统畸形病例为30%(95%CI 19-43%,I²=65%)。
  • WGS对意义不明变异(VUS)的增量检出率为18%(95%CI 7-33%,I²=74%)。
  • WGS相较于QF-PCR/CMA和ES的增量检出率为1%(95%CI 0-4%,I²=47%)。
  • WGS的合并中位周转时间为18天(范围1-912天),所需DNA量为100±0 ng,QF-PCR/CMA和ES为350±50 ng(P=0.03)。

关键数值与推荐

  • WGS相较于QF-PCR/CMA的增量检出率:全部26%(95%CI 18-36%),产前16%(95%CI 9-24%),产后39%(95%CI 27-51%)。
  • WGS相较于QF-PCR/CMA和ES的增量检出率:1%(95%CI 0-4%)。
  • WGS对VUS的增量检出率:18%(95%CI 7-33%)。
  • WGS所需DNA量:100±0 ng;QF-PCR/CMA和ES所需DNA量:350±50 ng(P=0.03)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • WGS相较于ES的增量检出率尚未得到证实。
  • WGS的VUS检出率相对较高。
  • 各合并增量检出率存在异质性,全部病例I²=86%,产前队列I²=85%,产后队列I²=53%,VUS分析I²=74%,WGS相较于QF-PCR/CMA和ES分析I²=47%,符合NHS England标准亚组I²=70%,多系统畸形亚组I²=65%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: First, to determine the incremental yield of whole-genome sequencing (WGS) over quantitative fluorescence polymerase chain reaction (QF-PCR)/chromosomal microarray analysis (CMA) with and without exome sequencing (ES) in fetuses, neonates and infants with a congenital anomaly that was or could have been detected on prenatal ultrasound. Second, to evaluate the turnaround time (TAT) and quantity of DNA required for testing using these pathways. METHODS: This review was registered prospectively in December 2022. Ovid MEDLINE, EMBASE, MEDLINE (Web of Science), The Cochrane Library and ClinicalTrials.gov databases were searched electronically (January 2010 to December 2022). Inclusion criteria were cohort studies including three or more fetuses, neonates or infants with (i) one or more congenital anomalies; (ii) an anomaly which was or would have been detectable on prenatal ultrasound; and (iii) negative QF-PCR and CMA. In instances in which the CMA result was unavailable, all cases of causative pathogenic copy number variants > 50 kb were excluded, as these would have been detectable on standard prenatal CMA. Pooled incremental yield was determined using a random-effects model and heterogeneity was assessed using Higgins' I2 test. Subanalyses were performed based on pre- or postnatal cohorts, cases with multisystem anomalies and those meeting the NHS England prenatal ES inclusion criteria. RESULTS: A total of 18 studies incorporating 902 eligible cases were included, of which eight (44.4%) studies focused on prenatal cohorts, incorporating 755 cases, and the remaining studies focused on fetuses undergoing postmortem testing or neonates/infants with congenital structural anomalies, constituting the postnatal cohort. The incremental yield of WGS over QF-PCR/CMA was 26% (95% CI, 18-36%) (I2 = 86%), 16% (95% CI, 9-24%) (I2 = 85%) and 39% (95% CI, 27-51%) (I2 = 53%) for all, prenatal and postnatal cases, respectively. The incremental yield increased in cases in which sequencing was performed in line with the NHS England prenatal ES criteria (32% (95% CI, 22-42%); I2 = 70%) and in those with multisystem anomalies (30% (95% CI, 19-43%); I2 = 65%). The incremental yield of WGS for variants of uncertain significance (VUS) was 18% (95% CI, 7-33%) (I2 = 74%). The incremental yield of WGS over QF-PCR/CMA and ES was 1% (95% CI, 0-4%) (I2 = 47%). The pooled median TAT of WGS was 18 (range, 1-912) days, and the quantity of DNA required was 100 ± 0 ng for WGS and 350 ± 50 ng for QF-PCR/CMA and ES (P = 0.03). CONCLUSION: While WGS in cases with congenital anomaly holds great promise, its incremental yield over ES is yet to be demonstrated. However, the laboratory pathway for WGS requires less DNA with a potentially faster TAT compared with sequential QF-PCR/CMA and ES. There was a relatively high rate of VUS using WGS. © 2023 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Shreeve N, Sproule C, Choy KW, et al. Incremental yield of whole-genome sequencing over chromosomal microarray analysis and exome sequencing for congenital anomalies in prenatal period and infancy: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2024. PMID: 37725747. doi:10.1002/uog.27491

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。